Naturopathic Oncology for Advanced Cancers: Survival Outcomes from the Canadian/US Integrative Oncology Study
CAND Journal · 2025
DOI: 10.54434/candj.206 ↗Kurz gefasst
Fachartikel in der Zeitschrift CAND Journal, 2025. Verfasst von Leanna J. Standish und 17 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Several traditional, complementary, and integrative therapies have been studied for their effect on cancer outcomes; however, few studies have evaluated naturopathic oncology in a real-world setting. We conducted an observational cohort study to evaluate whether consulting with a naturopathic doctor (ND) improves survival in people with advanced cancers.
Methods
Participants with metastatic breast, metastatic colorectal, advanced ovarian, or advanced pancreatic cancer were recruited from 12 North American naturopathic clinics. The primary outcome was 5-year overall survival compared with a matched cohort from the Surveillance Epidemiology and End Results (SEER) registry. We additionally evaluated survival based on the number of ND visits and intravenous vitamin C (IVC), intravenous mistletoe, and hyperthermia treatments.
Results
400 participants were enrolled: 165 had breast cancer, 116 had colorectal cancer, 72 had ovarian cancer, and 47 had pancreatic cancer. A bootstrapped analysis showed no significant differences in 5-year survival compared with SEER (breast: median hazard ratio [HR] 1.10, 95% confidence interval [CI] 0.80–1.54; colorectal: median HR 0.95, 95% CI 0.68–1.31; ovarian: median HR 1.08, 95% CI 0.64–1.86; pancreatic: median HR 0.76, 95% CI 0.51–1.13). Higher survival odds were seen with increasing IVC treatments in breast cancer, and with increasing ND visits in all cancer types except ovarian.
Conclusion
No survival benefits were seen in patients with advanced cancers who saw an ND compared with registry data. After controlling for survivorship bias, in general, the number of ND visits positively correlated with improved survival; however, the number of select naturopathic treatments did not. Findings should be interpreted with caution given study limitations.
Zitieren
APA
Standish, L. J., Sweet, E., Chiang, P. F., Legacy, M., Conte, E., Rizzolo, E., Dale, L., Psihogios, A., Ennis, J., Parmar, G., Marsden, E., Reid, M., Rubin, D., Reilly, P., Traub, M., Naydis, E., Ramsay, T., & Seely, D. (2025). Naturopathic Oncology for Advanced Cancers: Survival Outcomes from the Canadian/US Integrative Oncology Study. CAND Journal. https://doi.org/10.54434/candj.206
Vancouver
Standish LJ, Sweet E, Chiang PF, Legacy M, Conte E, Rizzolo E, et al. Naturopathic Oncology for Advanced Cancers: Survival Outcomes from the Canadian/US Integrative Oncology Study. CAND Journal. 2025. doi:10.54434/candj.206
BibTeX
@article{Standish2025,
author = {Standish, Leanna J. and Sweet, Erin and Chiang, Peih F. and Legacy, Mark and Conte, Ellen and Rizzolo, Erica and Dale, Linda and Psihogios, Athanasios and Ennis, Juile and Parmar, Gurdev and Marsden, Eric and Reid, Michael and Rubin, Dan and Reilly, Paul and Traub, Michael and Naydis, Eleonora and Ramsay, Tim and Seely, Dugald},
title = {Naturopathic Oncology for Advanced Cancers: Survival Outcomes from the Canadian/US Integrative Oncology Study},
journal = {CAND Journal},
year = {2025},
doi = {10.54434/candj.206}
}
EUVIMED